These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25217774)

  • 1. Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.
    Bodelon C; Pfeiffer RM; Buys SS; Black A; Sherman ME
    J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25217774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
    Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME
    Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of transvaginal ultrasound in screening for ovarian cancer.
    Campbell S; Gentry-Maharaj A
    Climacteric; 2018 Jun; 21(3):221-226. PubMed ID: 29490504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
    Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW
    J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.
    Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D; Izmirlian G; Fouad M; Johnson CC; Gohagan JK;
    Am J Obstet Gynecol; 2005 Nov; 193(5):1630-9. PubMed ID: 16260202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
    Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
    Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
    Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
    Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
    Temkin SM; Miller EA; Samimi G; Berg CD; Pinsky P; Minasian L
    Eur J Cancer; 2017 Dec; 87():182-188. PubMed ID: 29156299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
    Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
    Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproducibility in the assessment of postmenopausal ovaries with transvaginal ultrasound.
    Modugno F; Weissfeld JL; Hill LM
    Gynecol Oncol; 2000 May; 77(2):289-92. PubMed ID: 10785480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for ovarian cancer in the general population.
    Gentry-Maharaj A; Menon U
    Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):243-56. PubMed ID: 22182415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
    Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
    JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
    Pinsky PF; Yu K; Kramer BS; Black A; Buys SS; Partridge E; Gohagan J; Berg CD; Prorok PC
    Gynecol Oncol; 2016 Nov; 143(2):270-275. PubMed ID: 27615399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early detection of familial ovarian cancer.
    Dørum A; Kristensen GB; Abeler VM; Tropé CG; Møller P
    Eur J Cancer; 1996 Sep; 32A(10):1645-51. PubMed ID: 8983269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Sharma A; Burnell M; Gentry-Maharaj A; Campbell S; Amso NN; Seif MW; Fletcher G; Brunel C; Turner G; Rangar R; Ryan A; Jacobs I; Menon U;
    Ultrasound Obstet Gynecol; 2013 Oct; 42(4):472-7. PubMed ID: 23456790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian status in healthy postmenopausal women: follow-up 12 months after transvaginal ultrasound.
    Bell RJ; Healy DL; Robertson DM; Jobling T; Oehler MK; Edwards A; Shekleton P; Oldham J; Piessens S; Teoh M; Mamers P; Taylor N; Walker F
    Menopause; 2009; 16(6):1149-55. PubMed ID: 19574938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
    Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
    Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Sharma A; Burnell M; Gentry-Maharaj A; Campbell S; Amso NN; Seif MW; Fletcher G; Brunell C; Turner G; Rangar R; Ryan A; Jacobs I; Menon U
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):228-35. PubMed ID: 26095052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations?
    Baldwin LM; Trivers KF; Matthews B; Andrilla CH; Miller JW; Berry DL; Lishner DM; Goff BA
    Ann Intern Med; 2012 Feb; 156(3):182-94. PubMed ID: 22312138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.